Literature DB >> 19632742

Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.

Barbara Horváth1, Judit Demeter, Nóra Eros, Judit Hársing, Judit Csomor, András Matolcsy, Gyula Bottlik, Gabriella Gyori, Márta Marschalkó, Sarolta Kárpáti.   

Abstract

Intravascular lymphoma is an uncommon, very aggressive extranodal non-Hodgkin lymphoma that most frequently involves the skin and central nervous system. Most cases are of B-cell origin; T-cell phenotype is extremely rare. Malignant cells proliferate within the lumens of capillaries, arterioles, venules, and small arteries; vascular occlusion is responsible for the clinical signs and symptoms. The prognosis of this high-grade B-cell lymphoma has improved since the introduction of the anti-CD20 monoclonal antibody, rituximab. We describe a case of B-cell intravascular lymphoma successfully treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisolone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632742     DOI: 10.1016/j.jaad.2008.12.045

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

Review 1.  [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].

Authors:  C Lamos; E Dippel
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

2.  Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma.

Authors:  Hanan Mohamed Mahmoud; Yasmin Nabil El-Sakhawy
Journal:  Hematol Rep       Date:  2011-11-16

3.  A case report of primary prostate intravascular large B cell lymphoma presenting as prostatic hyperplasia.

Authors:  Fang Zhu; Huaxiong Pan; Yin Xiao; Qiuhui Li; Tao Liu; Xinxiu Liu; Gang Wu; Juan Li; Liling Zhang
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.